Skip to main content

European Commission recommend Pfizer's pending acquisition of Hospira


Clinical courses


Clinical research courses

The European Commission (EC) has approved under the European Union (EU) Merger Regulation the Pfizer Inc's pending acquisition of Hospira, Inc. The Commission's decision includes Pfizer’s commitment to divest certain assets.

Completion of the transaction remains subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, governmental and regulatory approvals in certain other jurisdictions and other usual and customary closing conditions.

Pfizer is one of the world's premier innovative biopharmaceutical companies.

<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>